How Immune Checkpoint Inhibitors Are Changing the Treatment Landscape for Metastatic Melanoma
Metastatic melanoma has a high mortality rate and is refractory to traditional treatments, but recent clinical trials have shown significantly improved patient outcomes with checkpoint inhibitors. However, treating physicians may find its use challenging due to limited clinical experience and confidence in prescribing immunotherapies, especially among patient populations under-represented in clinical trials and in managing immune-related adverse events. This webinar will cover the current practices and challenges in management of metastatic melanoma, as well as insights on the future management of melanoma patients.
This activity has been designed to meet the educational needs of health care professionals involved in the diagnosis, treatment, or management of patients with metastatic melanoma.
Upon completion of this activity, participants will be better able to do the following:
- Explain the modes of action of available immunotherapies for treating metastatic melanoma
- Outline the rationale for the use of immune checkpoint inhibitors singly or in combination
- Discuss the evidence (clinical trial data) for the efficacy of immune checkpoint inhibitors in metastatic melanoma
- List immune-related adverse events (irAEs) that may occur with the use of immune checkpoint inhibitors and how they should be identified and managed
Professor Grant McArthur
Dr Matteo Carlino
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education and Elsevier that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Faculty||Relationship Identified With:|
|Professor Grant McArthur|
Research grant support from Celgene Corporation and Pfizer Inc.
Dr Matteo Carlino
Consultant, advisor for Bristol-Myers Squibb Company, MSD & Co., Inc., Novartis AG, Amgen Inc.
Non-faculty: Sandy Breslow; Alison Kemp; Bernard M. Abrams, MD; Lisa Sullivan; and Tina Garcia hereby state that neither they nor their spouse/life partner have had any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
This activity has been supported by an independent educational grant from Bristol-Myers Squibb Company.
Jointly provided by the Elsevier Office of Continuing Medical Education and In Vivo Academy.
CME CREDIT (PHYSICIANS)
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and In Vivo Academy. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME INQUIRIES/SPECIAL NEEDS
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, In Vivo Academy, and Bristol-Myers Squibb Company do not recommend the use of any agent outside of the labeled indications.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 1.00 AMA PRA Category 1 Credit(s)™
- 1.00 Non-physician